BlossomHill Therapeutics, Inc. (NASDAQ:BLSM)
| Market Cap | $421.97M-9.3% |
| Revenue (ttm) | $0 |
| Net Income | -$68.78M |
| EPS | -$10.35 |
| Shares Out | 29.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 270,735 |
| Open | $14.34 |
| Previous Close | $14.41 |
| Day's Range | $13.90 - $15.63 |
| 52-Week Range | $11.02 - $27.99 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $38.33(+164.16%) |
| Earnings Date | Feb 11, 2027 |
About BLSM
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
When insiders bought and sold
1 year · open-market trades onlyAnalyst consensus
2 firms rating BLSM in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 11, 2027Earnings report
$BLSM stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in BLSM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BLSM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BLSM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BLSM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BLSM from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BLSM
| VTIVanguard Morningstar Total Stock Market ETF | $3.43M |
| VXFVanguard Extended Market ETF | $1.49M |
| VTWOVanguard Russell 2000 ETF | $130.56K |
| VTWGVanguard Russell 2000 Growth ETF | $13.08K |
| VTWVVanguard Russell 2000 Value ETF | $4.81K |
| VTHRVanguard Russell 3000 ETF | $1.87K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BLSM’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple positive clinical catalysts including FDA alignment on dosage and Phase 2 advancement; strong pipeline progress in oncology programs.
